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Aims: Most treatments for type 2 diabetes fail over time, necessitating combination therapy. We investigated the safety, tolerability and
efﬁcacy of liraglutide monotherapy compared with glimepiride monotherapy over 2 years.
Methods: Participants were randomized to receive once-daily liraglutide 1.2 mg, liraglutide 1.8 mg or glimepiride 8 mg. Participants completing
the 1-year randomized, double-blind, double-dummy period could continue open-label treatment for an additional year. Safety data were
evaluated for the full population exposed to treatment, and efﬁcacy data were evaluated for the full intention-to-treat (ITT) and 2-year
completer populations. Outcome measures included change in glycosylated haemoglobin (HbA1c), fasting plasma glucose (FPG), body weight
and frequency of nausea and hypoglycaemia.
Results: For patients completing 2 years of therapy, HbA1c reductions were −0.6% with glimepiride versus −0.9% with liraglutide 1.2 mg
(difference: −0.37, 95% CI: −0.71 to −0.02; p = 0.0376) and −1.1% with liraglutide 1.8 mg (difference: −0.55, 95% CI: −0.88 to −0.21;
p = 0.0016). In the ITT population, HbA1c reductions were −0.3% with glimepiride versus −0.6% with liraglutide 1.2 mg (difference: −0.31,
95% CI: −0.54 to −0.08; p = 0.0076) and −0.9% with liraglutide 1.8 mg (difference: −0.60, 95% CI: −0.83 to −0.38; p < 0.0001). For both
ITT and completer populations, liraglutide was more effective in reducing HbA1c, FPG and weight. Over 2 years, rates of minor hypoglycaemia
[self-treatedplasma glucose <3.1 mmol/l (<56 mg/dl)]were signiﬁcantly lowerwith liraglutide 1.2 mg and 1.8 mg compared with glimepiride
(p < 0.0001).
Conclusion: Liraglutide monotherapy for 2 years provides signiﬁcant and sustained improvements in glycaemic control and body weight
compared with glimepiride monotherapy, at a lower risk of hypoglycaemia.
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Introduction
Asmonotherapy,mostantidiabeticagentsfailtomaintainlong-
term glycaemic control. Although at different rates, this has
beenshownintheUKProspectiveDiabetesStudy(UKPDS)[1]
and A Diabetes Outcome Progression Trial (ADOPT) [2] with
either metformin, sulphonylurea (SU), or thiazolidinedione
(TZD) monotherapy.
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Liraglutide is a once-daily glucagon-like peptide 1 (GLP-1)
analogue for treatment of type 2 diabetes with 97% homology
to human GLP-1. It is safe and effective when used alone or in
combinationwithmetformin [3–5],anSU [4,6],metformin+
TZD [7] or metformin + SU [4,8]. In the 52-week Liraglutide
Effect and Action in Diabetes (LEAD)-3 trial [9], liraglutide
monotherapy produced greater reductions in glycosylated
haemoglobin (HbA1c) (primary endpoint), fasting plasma
glucose (FPG), body weight and systolic blood pressure (SBP)
than glimepiride 8 mg monotherapy, with fewer episodes of
hypoglycaemia.At the 1.8 mg dose, liraglutide produced stable
glycaemic control, with HbA1c levels unchanged at 52 weeks,
as compared to the 12-week nadir.
The objective of this 52-week open-label LEAD-3 extension
was not only to evaluate the long-term (2-year) safety,DIABETES, OBESITY AND METABOLISM original article
tolerability and efﬁcacy of liraglutide monotherapy compared
with glimepiride monotherapy, but also to assess durability of
glycaemic control, using various analytical procedures.
Research Design and Methods
Participants and Trial Design
LEAD-3 was a 104-week, phase 3, multicentre (126 US and 12
Mexican sites), active-control, parallel-group trial with an ini-
tial 52-week randomized, double-blind, double-dummy treat-
ment period [9] followed by a 52-week open-label extension.
Participantswithtype2diabetes[18–80 years,bodymassindex
≤45 kg/m2, screening HbA1c 7–11% (53–97 mmol/mol) on
diet/exercise or 7–10% (53–86 mmol/mol) on oral antidi-
abetic drug monotherapy] were randomized (1 : 1 : 1) to
receive once-daily subcutaneous liraglutide 1.2 mg, liraglutide
1.8 mg ororalglimepiride 8 mg. Participantsremained in their
original randomized treatment group with no dose changes
during the extension. Inclusion/exclusion and withdrawal cri-
teriahave been reported previously [9]. Participantswith three
consecutive FPG values >13.3 mmol/l (240 mg/dl) after week
8a n d>12.2 mmol/l (220 mg/dl) after week 28, or who did
not achieve adequate glycaemic control in the opinion of the
investigator, were withdrawn for ‘ineffective therapy’.
The trial was conducted from 7 February 2006 to 10
November 2008. Participants were unblinded to treatment
allocation at their ﬁrst visit after the 1-year database
release (22 November 2007). This trial is registered with
ClinicalTrials.gov (NCTC00294723) and was conducted in
compliance with Declaration of Helsinki and Good Clinical
Practice guidelines [10]. All amendments were approved by
localinstitutional review boards. Participants provided written
informed consent prior to any trial activities and continuation
in the extension.
The primary endpoint of the LEAD-3 trial was the change
in HbA1c from baseline to week 52. All endpoints for the
extension were secondary endpoints, with the key extension
efﬁcacy variable being the change in HbA1c from baseline
to week 104. Secondary efﬁcacy variables, described in the
previous report [body weight, waistcircumference, FPG,mean
postprandial plasma glucose (PPG) from eight-point self-
measured plasma glucose proﬁles, SBP, homeostasis model
assessment of β-cell function (HOMA-B), homeostasis model
assessment of insulin resistance (HOMA-IR), pro-insulin to
insulin ratio, and fasting glucagon, insulin and C-peptide]
were also evaluated at 104 weeks. Safety assessments were
identical to those reported previously and key assessments
included adverse events, hypoglycaemia and calcitonin [9].
Statistical Analyses
As extension efﬁcacy results can be inﬂuenced by choice of
analysis set and types of statistical evaluations, we analysed
two different populations (ﬁgure 1), intention-to-treat (ITT)
and completers, and used various statistical methods to handle
missing efﬁcacy data. Between-treatment-group comparisons
of efﬁcacy outcomes were analysed by analysis of covariance
(ancova) with treatment, country, and previous antidiabetes
treatment as ﬁxed effects and baseline as covariate. ancova
Figure 1. Participant ﬂow during the LEAD-3 trial. ITT, intention-to-treat.
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analyses of completers did not have imputation. For ITT
analyses, missing values were imputed using last observation
carried forward (LOCF), enabling all data (even from
participantswhowithdrewearly)tobeanalysedatweek104.In
addition, post-baseline estimates and treatment comparisons
were obtained using repeated-measures ancova [Proc Mixed
procedure with repeated statement from sas version 9.1.3
(sas Institute, Cary, NC, USA)]. This robust model reduced
variability at each post-baseline timepoint by taking into
account the overall trend of data for each treatment group;
signiﬁcance (p < 0.05) was determined for each post-baseline
timepoint without adjusting the signiﬁcance level. National
Glycohemoglobin Standardization Program (NGSP) HbA1c
values (in %) were converted into International Federation
of Clinical Chemistry (IFCC) values (in mmol/mol) using the
master equation: IFCC = 10.93 NGSP − 23.50.
The full safety analysis set (all participants exposed to
treatment) was used for all safety outcomes. Hypoglycaemia
eventrateswerecomparedusingageneralizedlinearmodelwith
treatment and country as ﬁxed effects under negative binomial
distribution. Other safety outcomes and demographic data
were presented using descriptive statistics. Cumulative adverse
events over 2 years are reported.
Funding Source and Role of the Sponsor
Novo Nordisk sponsored this trial and contributed to protocol
design,statisticalanalysisplans for1-yearand 2-yeardata,data
management, statistical analyses, and reporting of results. The
authors participated in trial design and had full access to both
1-yearand2-yeardata.Theauthorsparticipatedinwritingand
editing manuscript drafts, and assume full responsibility for
the data reported herein; authors made the ﬁnal decision to
submit this manuscript for publication.
Results
As shown in ﬁgure 1, 487/746 (65%) randomized participants
completed 1 year of double-blinded treatment, 440/487 (90%)
continued in the extension and 321/440 (73%) completed
2 years (43% of the original randomized population).
Of all randomized participants, fewer withdrew during
year 2 (119/746, 16%) than during year 1 (259/746, 35%).
Withdrawals for various reasons for year 2 were comparable
between groups (ﬁgure 1). During the second year, the
most common reason for trial withdrawal was ‘other’ (e.g.
participants who withdrew consent, were lost to follow-up, or
moved)intheliraglutidegroupsand‘ineffectivetherapy’inthe
glimepiride group (ﬁgure 1). Demographic characteristics for
randomized participants and 2-year completers were similar
overall, but 2-year completers had slightly lower mean HbA1c,
FPG and duration of diabetes (Table 1).
As extension trials tend to show survivor bias and to
ensure that potential bias was minimized, two populations
were evaluated: 2-year completers and the full ITT population.
Mean HbA1c over time was plotted for 2-year completers
(observed values, no imputation) in ﬁgure 2A; using ancova
withnoimputation,estimatedHbA1creductionsfrombaseline
to 2 years were signiﬁcantly greater with liraglutide 1.2 mg
[−0.9%;estimatedtreatmentdifference(ETD):−0.37,95%CI:
Table 1. Participant demographics and baseline (at randomization) characteristics.
Liraglutide 1.2 mg Liraglutide 1.8 mg Glimepiride 8 mg
All randomized 2-year completers All randomized 2-year completers All randomized 2-year completers
N 251 110 247 114 248 97
Men, n (%) 117 (47) 48 (44) 121 (49) 56 (49) 133 (54) 60 (62)
Age, years 53.7 (11.0) 53.8 (10.5) 52.0 (10.8) 52.8 (8.8) 53.4 (10.9) 54.0 (9.7)
Race, n (%)
White 200 (80) 94 (85) 186 (75) 86 (75) 192 (77) 80 (82)
Black 34 (14) 7 (6) 30 (12) 16 (14) 30 (12) 8 (8)
A s i a n 5( 2 ) 2( 2 ) 1 2( 5 ) 3( 3 ) 9( 4 ) 1( 1 )
Other 12 (5) 7 (6) 19 (8) 9 (8) 17 (7) 8 (8)
Hispanic ethnicity, n (%) 81 (32) 43 (39) 87 (35) 44 (39) 93 (38) 50 (52)
BMI, kg/m2 33.2 (5.6) 33.2 (5.5) 32.8 (6.3) 33.0 (6.4) 33.2 (5.6) 32.5 (5.6)
Duration diabetes, years 5.2 (5.5) 4.4 (5.5) 5.3 (5.1) 4.5 (4.5) 5.6 (5.1) 4.9 (4.7)
Previous treatment, n (%)
Diet/exercise 91 (36) 41 (37) 87 (35) 43 (38) 94 (38) 33 (34)
OAD monotherapy 160 (64) 69 (63) 160 (65) 71 (62) 154 (62) 64 (66)
HbA1c, %∗ 8.2 (1.1) 8.0 (1.0) 8.2 (1.1) 8.1 (1.0) 8.2 (1.1) 8.0 (1.0)
Weight, kg 92.1 (19.0) 92.0 (19.1) 92.6 (20.8) 92.6 (20.8) 93.3 (19.0) 90.5 (17.5)
FPG, mmol/l 9.3 (2.6) 8.7 (2.1) 9.5 (2.6) 9.1 (2.2) 9.5 (2.6) 8.7 (2.1)
SBP, mmHg 127.6 (14.3) 125.2 (12.0) 128.0 (13.9) 128.6 (14.7) 130.0 (16.1) 129.5 (16.7)
HOMA-B, % 65.6 (50.2) 72.2 (50.3) 65.5 (62.7) 74.4 (75.1) 74.9 (89.6) 74.8 (71.2)
HOMA-IR, % 7.0 (6.7) 6.4 (3.8) 6.9 (5.6) 6.9 (5.8) 7.5 (6.2) 6.6 (4.4)
Data are mean (s.d.) unless otherwise noted. HbA1c, weight, FPG and SBP values are from randomization (week 0). All other values are from screening.
BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycosylated haemoglobin; HOMA-B, homeostasis model assessment of β-cell function;
HOMA-IR, homeostasis model assessment of insulin resistance; OAD, oral antidiabetic drug; SBP, systolic blood pressure.
∗HbA1c values of 8.0, 8.1 and 8.2% are equivalent to 64, 65 and 66 mmol/mol, respectively.
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Figure 2. HbA1covertime.(A)Two-yearcompleterpopulation,observed
mean values, no imputation. (B) Intention-to-treat (ITT) population,
observed mean values, no imputation. (C) ITT population, estimated least
square (LS) mean values derived from an analysis of covariance (ANCOVA)
model with repeated measures. (D) Two-year completer population,
participants previously treated with diet and exercise, observed mean
values, no imputation. Error bars are ±2s.e. Panel C: ∗p < 0.0001 vs.
glimepiride; ∗∗p < 0.05 vs. glimepiride.
−0.71 to −0.02; p = 0.0376] and liraglutide 1.8 mg (−1.1%;
ETD: −0.55, 95% CI: −0.88 to −0.21; p = 0.0016 ) compared
with glimepiride (−0.6%).
MeanHbA1cover2 yearsisplottedfortheITTpopulationin
ﬁgure 2B(observedvalues,noimputation);usingancovawith
LOCF imputation, estimated HbA1c reductions from baseline
to 2 years were signiﬁcantly greater with liraglutide 1.2 mg
(−0.6%; ETD: −0.31, 95% CI: −0.54 to −0.08; p = 0.0076)
and liraglutide 1.8 mg (−0.9%; ETD: −0.60, 95% CI: −0.83
to −0.38; p < 0.0001) compared with glimepiride (−0.3%).
Although the HbA1c reductions from baseline were smaller
in the ITT (LOCF) analysis set compared with the 2-year
completer analysis set, ETDs were very similar. In addition,
estimated values of HbA1c from a repeated-measures ancova
were signiﬁcantly different between liraglutide and glimepiride
at all post-baseline timepoints (ﬁgure 2C, ITT population).
Thirty-six percent of 2-year completers were drug-naive at
trial entry; mean HbA1c values over 2 years are presented in
ﬁgure 2D.
More 2-year completers treated with liraglutide reached
the American Diabetes Association (ADA) HbA1c target of
<7% (<53 mmol/mol) and the more stringent International
Diabetes Federation (IDF)/American Association of Clinical
Endocrinologists (AACE) target of ≤6.5% (≤48 mmol/mol)
compared with glimepiride (ﬁgure 3A). In 2-year completers,
FPG declined early in the trial and these decreases were
maintained (ﬁgure 3B), and liraglutide was signiﬁcantly more
effective than glimepiride in reducing FPG (ﬁgure 3C).
Reductions in mean PPG were −1.9, −2.6 and −1.8 mmol/l
for liraglutide 1.2 mg, liraglutide 1.8 mg and glimepiride
(p = 0.0103 for liraglutide 1.8 mg vs. glimepiride).
In 2-year completers, mean body weight decreased over the
ﬁrst 12 weeks of therapy and decreases were maintained over
2 yearsinbothliraglutidegroups;theglimepiridegroupgained
weight (ﬁgure 3D). Differences between treatment groups
were statistically signiﬁcant (ﬁgure 3E). Participants also had
signiﬁcant reductions in waist circumference with liraglutide
1.2 mg (4.0 cm) and liraglutide 1.8 mg (4.9 cm) compared
with glimepiride (1.0 cm) (p = 0.0413 for liraglutide 1.2 mg
and p = 0.0095 for liraglutide 1.8 mg vs. glimepiride).
In 2-year completers, HOMA-IR decreased by 1.1% with
liraglutide 1.2 mg and 0.8% with liraglutide 1.8 mg and
increased by 0.8% with glimepiride (p = 0.0451 for liraglutide
1.2 mg vs. glimepiride). Pro-insulin to insulin ratio increased
slightlyinallgroups,by0.108withliraglutide1.2mg,0.018with
liraglutide1.8 mgand0.141withglimepiride(withsigniﬁcantly
less of an increase with liraglutide 1.8 mg vs. glimepiride;
p = 0.0394). After 2 years, all three groups had increases in
HOMA-B, fasting insulin and fasting C-peptide, and had
decreases in fasting glucagon, but the differences between
groups were not signiﬁcant. No signiﬁcant differences between
groups in change in pulse, diastolic blood pressure (DBP)
and SBP were observed in participants completing 2 years.
Although the SBP differences were not signiﬁcant at week
104, there were signiﬁcantly greater reductions with liraglutide
versus glimepiride at the majority of timepoints [weeks 2, 4, 8,
12, 20, 40, 76 (1.8 mg only) and 92] using a repeated-measures
ancova analysis.
Besides HbA1c, all other efﬁcacy endpoints were also anal-
ysed using the full ITT analysis set (ancova,L O C F )( T a b l e2 ) .
Estimated mean treatment differences for the ITT population
were similar to 2-year completers with signiﬁcantly greater
reductions in FPG, body weight, waist circumference and
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Figure 3. Additionalefﬁcacyendpointsfor2-yearcompleters. (A)Percentageofparticipants treatedtoHbA1ctargets<7%(<53 mmol/mol) (leftgraph)
and ≤6.5% (≤48 mmol/mol) (right graph) at 2 years. (B) Fasting plasma glucose (FPG) (mmol/l) over time. (C) Change in FPG (mmol/l) from baseline
to week 104. (D) Body weight (kg) over time. (E) Change in body weight (kg) from baseline to week 104. Data in panel A are estimated percentages from
a logistic regression model. Data in panels B and D are observed means. Data in panels C and E are least square (LS) means from an analysis of covariance
(ANCOVA) model. Error bars are ±2s.e. ETD = estimated treatment difference (liraglutide–glimepiride).
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Table 2. Change from baseline to week 104 for secondary efﬁcacy parameters [intention-to-treat (ITT) Population].
Liraglutide 1.2 mg Liraglutide 1.8 mg Glimepiride 8 mg
Endpoint  
ETD [95% CI] and p-value
versus glimepiride  
ETD [95% CI] and p-value
versus glimepiride  
HbA1c, % −0.6 −0.31 [−0.54; −0.08], 0.0076 −0.9 −0.60 [−0.83; −0.38], <0.0001 −0.3
HbA1c <7% (<53 mmol/mol),
%p a r t i c i p a n t s ∗
36.9 1.98 [1.30; 3.00], 0.0015 44.4 2.81 [1.85; 4.26], <0.0001 23.2
HbA1c ≤6.5%, (<48 mmol/mol)
%p a r t i c i p a n t s ∗
25.0 1.84 [1.15; 2.95], 0.0113 29.9 2.39 [1.50; 3.80], 0.0002 15.4
FPG, mmol/l −0.52 −0.63 [−1.17; −0.09], 0.0217 −0.88 −0.99 [−1.53; −0.45], 0.0003 0.11
PPG, mmol/l −1.52 −0.14 [−0.66; 0.39], 0.6060 −2.06 −0.68 [−1.21; −0.16], 0.0105 −1.38
Body weight, kg −1.89 −2.84 [−3.63; −2.06], <0.0001 −2.70 −3.65 [−4.44; −2.86], <0.0001 0.95
Waist circumference, cm −3.48 −3.08 [−4.72; −1.44], 0.0002 −3.73 −3.33 [−4.98; −1.69], <0.0001 −0.40
HOMA-B, % 20.63 3.72 [−21.91; 29.34], 0.7757 24.66 7.74 [−18.10; 33.58], 0.5565 16.91
HOMA-IR, % −0.38 −1.50 [−2.92; −0.08], 0.0388 −0.86 −1.99 [−3.42; −0.55], 0.0067 1.13
Fasting insulin, pmol/l −2.03 −17.91 [−41.65; 5.83], 0.1390 −1.86 −17.74 [−41.71; 6.24], 0.1468 15.88
Fasting C-peptide, nmol/l 10.05 −0.51 [−9.47; 8.46], 0.9117 14.36 3.80 [−5.27; 12.87], 0.4104 10.56
Pro-insulin/insulin ratio 0.05 −0.05 [−0.12; 0.02], 0.1403 0.01 −0.10 [−0.17; −0.03], 0.0045 0.10
Fasting glucagon, pg/ml −11.85 −6.86 [−13.52; −0.21], 0.0433 −9.92 −4.93 [−11.69; 1.84], 0.1535 −4.99
SBP, mmHg −1.35 −0.86 [−3.18; 1.46], 0.4657 −2.37 −1.88 [−4.21; 0.45], 0.1135 −0.49
DBP, mmHg −0.58 −0.14 [−1.50; 1.23], 0.8429 −0.81 −0.37 [−1.74; 1.00], 0.5965 −0.44
Pulse, bpm 2.04 1.36 [−0.17; 2.90], 0.0821 0.92 0.24 [−1.30; 1.78], 0.7589 0.67
  = Change from baseline to the end of the trial (week 104), ITT (last observation carried forward). Data are least square means, unless otherwise noted.
p-values from statistically signiﬁcant comparisons are in bold text. bpm, beats per minute; CI, conﬁdence interval; DBP, diastolic blood pressure; ETD,
estimated treatment difference (liraglutide–glimepiride); FPG, fasting plasma glucose; HbA1c, glycosylated haemoglobin; HOMA-B, homeostasis model
assessment of β-cell function; HOMA-IR, homeostasis model assessment of insulin resistance; PPG, postprandial plasma glucose; SBP, systolic blood
pressure.
∗Percentage reaching target from a logistic regression model and odds ratio presented rather than treatment difference.
HOMA-IR, and signiﬁcantly greater increases in proportion of
participants reaching HbA1c targets of <7% (<53 mmol/mol)
and≤6.5%(≤48 mmol/mol)forliraglutide1.2 mgand 1.8 mg
comparedwithglimepiride.Incontrasttothe2-yearcompleter
population, the ITT population had signiﬁcant reductions
with liraglutide 1.2 mg compared with glimepiride in fasting
glucagonandwithbothliraglutide1.2 mgand1.8 mgcompared
with glimepiride in HOMA-IR. As with completers, there were
no signiﬁcant differences between treatment groups in SBP,
DBP, pulse and HOMA-B after 2 years in the ITT population.
Adverse events (system organ classes and preferred terms)
reported by at least 5% of participants during the 2-year
trial period are summarized for the entire safety population;
gastrointestinal adverse events were more common with
liraglutide (Table 3). With liraglutide, nausea was most
frequently reported early in the trial and remained below
5% throughout the extension. No participants withdrew from
the extension because of nausea.
Over 2 years, 28 serious adverse events were reported by
23 (9.2%) participants using liraglutide 1.2 mg, 30 events by
22 (8.9%) participants using liraglutide 1.8 mg and 32 events
by 20 (8.1%) participants using glimepiride. Most events were
‘unlikely’ related to trial drug with 12 serious adverse events
judged to have a ‘possible’ relationship (Appendix S2). During
the extension, there was 1 fatality after 669 days of treatment
with liraglutide 1.8 mg. The participant died at home 3 days
after a colonoscopy and biopsy of a polyp; autopsy revealed
signs of acute and chronic pancreatitis and cholelithiasis. No
amylase or lipase measurements were available.
Over 2 years, 12, 10 and 26% of participants had minor
hypoglycaemia [self-treated plasma glucose <3.1 mmol/l
(56 mg/dl)] in the liraglutide 1.2 mg, liraglutide 1.8 mg
and glimepiride groups, respectively. The rate of minor
hypoglycaemiawas0.21eventsperpatient-yearwithliraglutide
1.2 mgand0.22withliraglutide1.8 mg,signiﬁcantlylowerthan
1.75 with glimepiride (p < 0.0001 for both comparisons vs.
glimepiride). One event of major hypoglycaemia (liraglutide
1.8 mg group) occurred after regular insulin was infused as
part of a substudy procedure. No increases in mean calcitonin
levels were observed over 2 years and allmean values remained
in the lower end of the normal range (<1.1 pg/ml).
Discussion
Long-term head-to-head comparative studies of antidiabetes
monotherapies are rare. Two-year results from published
head-to-head studies comparing antidiabetic monotherapies
showed greater HbA1c reductions with rosiglitazone 8 mg and
metformin 2 g than glyburide 15 mg in ADOPT [2] and signif-
icantly greater reductions in HbA1c with once-daily rosiglita-
zone 8 mg compared with twice-daily vildagliptin 50 mg [11].
While there have been no published results from long-term
controlled studies of GLP-1 receptor agonists as monother-
apy, pooled 2-year results from three open-label, uncontrolled
extensions of exenatide added on to metformin, SU, or both
have been published and showed improvements in glycaemic
control and weight [12]. Our trial, LEAD-3, was designed as
a parallel-group, head-to-head monotherapy trial evaluating
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Table 3. Treatment-emergentadverseeventsover2 yearsbysystemorganclassandpreferredtermreportedby≥5%inanyonegroup(safetypopulation).
Liraglutide 1.2 mg
(N = 251)
Liraglutide 1.8 mg
(N = 246)
Glimepiride 8 mg
(N = 248)
All adverse events 213 (85%) 207 (84%) 194 (78%)
Gastrointestinal disorders 135 (54%) 130 (53%) 70 (28%)
Constipation 21 (8%) 29 (12%) 12 (5%)
Diarrhoea 44 (18%) 48 (20%) 23 (9%)
Flatulence 4 (2%) 13 (5%) 5 (2%)
Nausea 72 (29%) 75 (31%) 21 (9%)
Vomiting 33 (13%) 25 (10%) 10 (4%)
Cardiac disorders 8 (3%) 11 (5%) 14 (6%)
Eye disorders 15 (6%) 14 (6%) 16 (7%)
General disorders and administration site conditions 42 (17%) 51 (21%) 39 (16%)
Fatigue 8 (3%) 13 (5%) 9 (4%)
Infections and infestations 134 (53%) 124 (50%) 114 (46%)
Bronchitis 15 (6%) 9 (4%) 11 (4%)
Inﬂuenza 23 (9%) 27 (11%) 21 (9%)
Nasopharyngitis 23 (9%) 16 (7%) 18 (7%)
Sinusitis 21 (8%) 18 (7%) 18 (7%)
Upper respiratory tract infection 36 (14%) 33 (13%) 22 (9%)
Urinary tract infection 26 (10%) 15 (6%) 13 (5%)
Injury, poisoning and procedural complications 32 (13%) 35 (14%) 37 (15%)
Investigations 23 (9%) 31 (13%) 25 (10%)
Metabolism and nutrition disorders 45 (18%) 42 (17%) 36 (15%)
Musculoskeletal, connective tissue disorders 61 (24%) 61 (25%) 58 (23%)
Arthralgia 11 (4%) 6 (2%) 15 (6%)
Back pain 18 (7%) 18 (7%) 17 (7%)
Pain in extremity 9 (4%) 15 (6%) 8 (3%)
Nervous system disorders 65 (26%) 58 (24%) 58 (23%)
Dizziness 13 (5%) 19 (8%) 13 (5%)
Headache 28 (11%) 18 (7%) 23 (9%)
Psychiatric disorders 24 (10%) 28 (11%) 16 (7%)
Depression 8 (3%) 14 (6%) 5 (2%)
Renal and urinary disorders 13 (5%) 11 (5%) 15 (6%)
Reproductive system and breast disorders 12 (5%) 14 (6%) 12 (5%)
Respiratory, thoracic and mediastinal disorders 23 (9%) 42 (17%) 36 (15%)
Cough 5 (2%) 14 (6%) 11 (4%)
Skin and subcutaneous tissue disorders 26 (10%) 31 (13%) 20 (8%)
Vascular disorders 20 (8%) 20 (8%) 20 (8%)
Hypertension 14 (6%) 11 (5%) 17 (7%)
Data are n (%).
the 2-year safety and efﬁcacy of liraglutide (1.2 and 1.8 mg)
compared with glimepiride 8 mg. Over 2 years, liraglutide
monotherapy provided signiﬁcantly greater improvements in
glycaemiccontroland body weight compared with glimepiride
monotherapy, at a lower risk of hypoglycaemia.
With regard to the trial design of LEAD-3, one difference
from prior long-term monotherapy trials [2,11] was that only
onethirdofparticipantsinLEAD-3werepreviouslydrug-naive.
Hence,substitutionofliraglutideforanotherantidiabetesther-
apy could underestimate the treatment effect compared with
studies where all participants were drug-naive. Indeed, larger
HbA1c reductions occurred in the previously drug-naive sub-
group (−1.4% in 2-year completers) compared with the entire
trial population in LEAD-3. During the LEAD-3 extension,
unlike the exenatide extensions [12], participants remained in
their original randomized treatment group and drug doses
remained unchanged. Moreover, no rescue medications were
permitted. This allowed long-term comparative efﬁcacy and
safety to be assessed without these confounding factors. Lim-
itations of this trial included the open-label nature of the
extension, which can result in investigator and/or participant
bias, and the 57% withdrawal rate over 2 years.
We analysed and reported efﬁcacy outcomes both for all
participants completing 2 years of therapy and the original
ITT population, because efﬁcacy results from clinical trial
extensions can be inﬂuenced by the choice of analysis set.
Arguably, the most appropriate analysis set from a clinical
perspective would be the participants who completed the
trial, which would show the population of participants that
is most likely to tolerate a given therapy and what long-term
efﬁcacy and safety can be expected. Analyses of the entire
trial population (ITT or safety) give an overall picture of the
comparative efﬁcacy and safety between two treatments; these
are often preferred by regulatory authorities [13].
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Not surprisingly, some survivor bias was observed, in that
HbA1c reductions were greater for participants completing
the full 2 years than in the full ITT randomized population
(using no imputation for completers vs. LOCF for the ITT
population). This difference may arise from the inclusion of
data from participants who withdrew from the trial because of
ineffective therapy,non-compliance with the protocol,adverse
events, or other reasons. Participants who completed the trial
had greater initial reductions in glycaemic control and had
slightly lower HbA1c and FPG values at baseline. Despite
the small baseline differences between the ITT and completer
populations, the 2-year data were robust. Various populations
and analyses showed signiﬁcant and consistent treatment
beneﬁts of all three interventions, which were greater with
liraglutide compared with glimepiride.
For participants remaining in the trial (43% of randomized
participants), HbA1c levels after 2 years were similar to the
values after 1 year, providing evidence of sustained glycaemic
beneﬁt of liraglutide therapy for at least 2 years and superiority
of liraglutide as compared with glimepiride. These conclusions
are robust because each method of analysis yielded essentially
the same result. Moreover, participants treated with liraglutide
experiencedgreaterandsustainedweightlossthanthosetreated
with glimepiride, who gained weight.
With regard to safety, in the entire safety population, the
frequency of nausea with liraglutide remained low during the
extension, consistent with the conclusion made after the ﬁrst
year that nausea is transient with liraglutide. The rates of
minor hypoglycaemia associated with liraglutide were slightly
lower at year 2 than year 1 (0.21–0.22 vs. 0.30–0.25 events per
patient-year) [9].Over2 years,theriskofminorhypoglycaemia
was signiﬁcantly lower with liraglutide than glimepiride,
consistent with GLP-1 receptor agonists stimulating insulin
secretion in a glucose-dependent manner (i.e. only during
hyperglycaemia) compared with SUs stimulating secretion of
insulin at any blood glucose concentration. The frequency of
withdrawal during the second year of the trial was lower than
during the ﬁrst year, and no additional safety signals were
evident. Data concerning potential thyroid cancer effects of
chronic liraglutide administration were reassuring. Calcitonin
levels for the full 2-year period were far below the lower
limits of normal for the assay. Upward drift in calcitonin
levels was not seen in any treatment group at any time
interval.
In conclusion, glycaemic control, weight beneﬁts, and a low
rate ofhypoglycaemiawere observed after2 years of liraglutide
treatment. Longer-term data are needed to conﬁrm durability,
impact upon β-cell function, and safety.
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